CC BY 4.0 · Thromb Haemost 2019; 119(01): 104-116
DOI: 10.1055/s-0038-1676344
Cellular Haemostasis and Platelets
Georg Thieme Verlag KG Stuttgart · New York

Human Platelet Protein Ubiquitylation and Changes following GPVI Activation

Amanda J. Unsworth*
1   Department of Biochemistry, University of Oxford, Oxford, United Kingdom
2   Institute for Cardiovascular and Metabolic Research, University of Reading, Reading, United Kingdom
Izabela Bombik*
1   Department of Biochemistry, University of Oxford, Oxford, United Kingdom
Adan Pinto-Fernandez
3   Nuffield Department of Medicine, Target Discovery Institute, University of Oxford, Oxford, United Kingdom
Joanna F. McGouran
3   Nuffield Department of Medicine, Target Discovery Institute, University of Oxford, Oxford, United Kingdom
Rebecca Konietzny
3   Nuffield Department of Medicine, Target Discovery Institute, University of Oxford, Oxford, United Kingdom
René P. Zahedi
4   JGH Proteomics Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
Steve P. Watson
5   Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom
6   Centre of Membrane Proteins and Receptors, Universities of Birmingham and Nottingham, The Midlands, United Kingdom
Benedikt M. Kessler**
3   Nuffield Department of Medicine, Target Discovery Institute, University of Oxford, Oxford, United Kingdom
Catherine J. Pears**
1   Department of Biochemistry, University of Oxford, Oxford, United Kingdom
› Author Affiliations
Funding This work was supported by grants from The British Heart Foundation (Grant references PG/11/121/29308 and PG/14/17/30720) and the EPA Cephalosporin Fund.
Further Information

Publication History

04 June 2018

10 October 2018

Publication Date:
31 December 2018 (online)


Platelet activators stimulate post-translational modification of signalling proteins to change their activity or their molecular interactions leading to signal propagation. One covalent modification is attachment of the small protein ubiquitin to lysine residues in target proteins. Modification by ubiquitin can either target proteins for degradation by the proteasome or act as a scaffold for other proteins. Pharmacological inhibition of deubiquitylases or the proteasome inhibition of platelet activation by collagen, demonstrating a role for ubiquitylation, but relatively few substrates for ubiquitin have been identified and the molecular basis of inhibition is not established. Here, we report the ubiquitome of human platelets and changes in ubiquitylated proteins following stimulation by collagen-related peptide (CRP-XL). Using platelets from six individuals over three independent experiments, we identified 1,634 ubiquitylated peptides derived from 691 proteins, revealing extensive ubiquitylation in resting platelets. Note that 925 of these peptides show an increase of more than twofold following stimulation with CRP-XL. Multiple sites of ubiquitylation were identified on several proteins including Syk, filamin and integrin heterodimer sub-units. This work reveals extensive protein ubiquitylation during activation of human platelets and opens the possibility of novel therapeutic interventions targeting the ubiquitin machinery.

* These authors contributed equally to this study.

** B.M.K. and C.J.P. are joint corresponding authors.

  • References

  • 1 Hughes CE, Pollitt AY, Mori J. , et al. CLEC-2 activates Syk through dimerization. Blood 2010; 115 (14) 2947-2955
  • 2 Gao J, Zoller KE, Ginsberg MH, Brugge JS, Shattil SJ. Regulation of the pp72syk protein tyrosine kinase by platelet integrin alpha IIb beta 3. EMBO J 1997; 16 (21) 6414-6425
  • 3 Poole A, Gibbins JM, Turner M. , et al. The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J 1997; 16 (09) 2333-2341
  • 4 Grabbe C, Husnjak K, Dikic I. The spatial and temporal organization of ubiquitin networks. Nat Rev Mol Cell Biol 2011; 12 (05) 295-307
  • 5 Yau R, Rape M. The increasing complexity of the ubiquitin code. Nat Cell Biol 2016; 18 (06) 579-586
  • 6 Bremm A, Komander D. Emerging roles for Lys11-linked polyubiquitin in cellular regulation. Trends Biochem Sci 2011; 36 (07) 355-363
  • 7 Mevissen TET, Komander D. Mechanisms of deubiquitinase specificity and regulation. Annu Rev Biochem 2017; 86: 159-192
  • 8 Avcu F, Ural AU, Cetin T, Nevruz O. Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro. Thromb Res 2008; 121 (04) 567-571
  • 9 Ostrowska JK, Wojtukiewicz MZ, Chabielska E, Buczko W, Ostrowska H. Proteasome inhibitor prevents experimental arterial thrombosis in renovascular hypertensive rats. Thromb Haemost 2004; 92 (01) 171-177
  • 10 Gupta N, Li W, Willard B, Silverstein RL, McIntyre TM. Proteasome proteolysis supports stimulated platelet function and thrombosis. Arterioscler Thromb Vasc Biol 2014; 34 (01) 160-168
  • 11 Gupta N, Li W, McIntyre TM. Deubiquitinases modulate platelet proteome ubiquitination, aggregation, and thrombosis. Arterioscler Thromb Vasc Biol 2015; 35 (12) 2657-2666
  • 12 Dangelmaier CA, Quinter PG, Jin J, Tsygankov AY, Kunapuli SP, Daniel JL. Rapid ubiquitination of Syk following GPVI activation in platelets. Blood 2005; 105 (10) 3918-3924
  • 13 Auger JM, Best D, Snell DC, Wilde JI, Watson SP. c-Cbl negatively regulates platelet activation by glycoprotein VI. J Thromb Haemost 2003; 1 (11) 2419-2426
  • 14 Yankee TM, Keshvara LM, Sawasdikosol S, Harrison ML, Geahlen RL. Inhibition of signaling through the B cell antigen receptor by the protooncogene product, c-Cbl, requires Syk tyrosine 317 and the c-Cbl phosphotyrosine-binding domain. J Immunol 1999; 163 (11) 5827-5835
  • 15 Thomas DH, Getz TM, Newman TN. , et al. A novel histidine tyrosine phosphatase, TULA-2, associates with Syk and negatively regulates GPVI signaling in platelets. Blood 2010; 116 (14) 2570-2578
  • 16 Reppschläger K, Gosselin J, Dangelmaier CA. , et al. TULA-2 protein phosphatase suppresses activation of Syk through the GPVI platelet receptor for collagen by dephosphorylating Tyr(P)346, a regulatory site of Syk. J Biol Chem 2016; 291 (43) 22427-22441
  • 17 Zhou Y, Abraham S, Renna S. , et al. TULA-2 (T-Cell Ubiquitin Ligand-2) inhibits the platelet fc receptor for IgG IIA (FcγRIIA) signaling pathway and heparin-induced thrombocytopenia in mice. Arterioscler Thromb Vasc Biol 2016; 36 (12) 2315-2323
  • 18 Senzel L, Gnatenko DV, Bahou WF. The platelet proteome. Curr Opin Hematol 2009; 16 (05) 329-333
  • 19 Watson SP, Bahou WF, Fitzgerald D, Ouwehand W, Rao AK, Leavitt AD. ; ISTH Platelet Physiology Subcommittee. Mapping the platelet proteome: a report of the ISTH Platelet Physiology Subcommittee. J Thromb Haemost 2005; 3 (09) 2098-2101
  • 20 O'Neill EE, Brock CJ, von Kriegsheim AF. , et al. Towards complete analysis of the platelet proteome. Proteomics 2002; 2 (03) 288-305
  • 21 Burkhart JM, Vaudel M, Gambaryan S. , et al. The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. Blood 2012; 120 (15) e73-e82
  • 22 Fong KP, Barry C, Tran AN. , et al. Deciphering the human platelet sheddome. Blood 2011; 117 (01) e15-e26
  • 23 Brophy TM, Raab M, Daxecker H. , et al. RN181, a novel ubiquitin E3 ligase that interacts with the KVGFFKR motif of platelet integrin alpha(IIb)beta3. Biochem Biophys Res Commun 2008; 369 (04) 1088-1093
  • 24 Pears CJ, Thornber K, Auger JM. , et al. Differential roles of the PKC novel isoforms, PKCdelta and PKCepsilon, in mouse and human platelets. PLoS One 2008; 3 (11) e3793
  • 25 Nielsen ML, Vermeulen M, Bonaldi T, Cox J, Moroder L, Mann M. Iodoacetamide-induced artifact mimics ubiquitination in mass spectrometry. Nat Methods 2008; 5 (06) 459-460
  • 26 Sobott F, Watt SJ, Smith J, Edelmann MJ, Kramer HB, Kessler BM. Comparison of CID versus ETD based MS/MS fragmentation for the analysis of protein ubiquitination. J Am Soc Mass Spectrom 2009; 20 (09) 1652-1659
  • 27 Bustos D, Bakalarski CE, Yang Y, Peng J, Kirkpatrick DS. Characterizing ubiquitination sites by peptide-based immunoaffinity enrichment. Mol Cell Proteomics 2012; 11 (12) 1529-1540
  • 28 Wessel D, Flügge UI. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem 1984; 138 (01) 141-143
  • 29 Rappsilber J, Ishihama Y, Mann M. Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal Chem 2003; 75 (03) 663-670
  • 30 Davis S, Charles PD, He L, Mowlds P, Kessler BM, Fischer R. Expanding proteome coverage with CHarge Ordered Parallel Ion aNalysis (CHOPIN) combined with broad specificity proteolysis. J Proteome Res 2017; 16 (03) 1288-1299
  • 31 Ternette N, Yang M, Laroyia M. , et al. Inhibition of mitochondrial aconitase by succination in fumarate hydratase deficiency. Cell Reports 2013; 3 (03) 689-700
  • 32 Tyanova S, Temu T, Sinitcyn P. , et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods 2016; 13 (09) 731-740
  • 33 Vizcaíno JA, Deutsch EW, Wang R. , et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat Biotechnol 2014; 32 (03) 223-226
  • 34 Hjerpe R, Aillet F, Lopitz-Otsoa F, Lang V, England P, Rodriguez MS. Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities. EMBO Rep 2009; 10 (11) 1250-1258
  • 35 Wagner SA, Beli P, Weinert BT. , et al. Proteomic analyses reveal divergent ubiquitylation site patterns in murine tissues. Mol Cell Proteomics 2012; 11 (12) 1578-1585
  • 36 Beck F, Geiger J, Gambaryan S. , et al. Temporal quantitative phosphoproteomics of ADP stimulation reveals novel central nodes in platelet activation and inhibition. Blood 2017; 129 (02) e1-e12
  • 37 Arthur JF, Shen Y, Gardiner EE. , et al. TNF receptor-associated factor 4 (TRAF4) is a novel binding partner of glycoprotein Ib and glycoprotein VI in human platelets. J Thromb Haemost 2011; 9 (01) 163-172
  • 38 Cappadocia L, Lima CD. Ubiquitin-like protein conjugation: structures, chemistry, and mechanism. Chem Rev 2018; 118 (03) 889-918
  • 39 Hwaiz R, Rahman M, Zhang E, Thorlacius H. Platelet secretion of CXCL4 is Rac1-dependent and regulates neutrophil infiltration and tissue damage in septic lung damage. Br J Pharmacol 2015; 172 (22) 5347-5359
  • 40 Goggs R, Williams CM, Mellor H, Poole AW. Platelet Rho GTPases-a focus on novel players, roles and relationships. Biochem J 2015; 466 (03) 431-442
  • 41 Tolmachova T, Abrink M, Futter CE, Authi KS, Seabra MC. Rab27b regulates number and secretion of platelet dense granules. Proc Natl Acad Sci U S A 2007; 104 (14) 5872-5877
  • 42 Hampson A, O'Connor A, Smolenski A. Synaptotagmin-like protein 4 and Rab8 interact and increase dense granule release in platelets. J Thromb Haemost 2013; 11 (01) 161-168
  • 43 Justa-Schuch D, Silva-Garcia M, Pilla E. , et al. DPP9 is a novel component of the N-end rule pathway targeting the tyrosine kinase Syk. eLife 2016; 5: 5
  • 44 Durrant TN, van den Bosch MT, Hers I. Integrin αIIbβ3 outside-in signaling. Blood 2017; 130 (14) 1607-1619
  • 45 Baig A, Bao X, Wolf M, Haslam RJ. The platelet protein kinase C substrate pleckstrin binds directly to SDPR protein. Platelets 2009; 20 (07) 446-457
  • 46 Canobbio I, Visconte C, Momi S. , et al. Platelet amyloid precursor protein is a modulator of venous thromboembolism in mice. Blood 2017; 130 (04) 527-536
  • 47 Humpel C. Platelets: their potential contribution to the generation of beta-amyloid plaques in Alzheimer's disease. Curr Neurovasc Res 2017; 14 (03) 290-298
  • 48 Zhang Y, Chen X, Zhao Y, Ponnusamy M, Liu Y. The role of ubiquitin proteasomal system and autophagy-lysosome pathway in Alzheimer's disease. Rev Neurosci 2017; 28 (08) 861-868
  • 49 Pinto-Fernandez A, Kessler BM. DUBbing cancer: deubiquitylating enzymes involved in epigenetics, DNA damage and the cell cycle as therapeutic targets. Front Genet 2016; 7: 133
  • 50 Lub S, Maes K, Menu E, De Bruyne E, Vanderkerken K, Van Valckenborgh E. Novel strategies to target the ubiquitin proteasome system in multiple myeloma. Oncotarget 2016; 7 (06) 6521-6537